The pharma group has presented phase 1/2 results with new candidate NXT007 at the International Society on Thrombosis and ...

Positive phase I/II data presented at the 2025 International Society on Thrombosis and Haemostasis (ISTH) Congress show NXT007 achieved no bleeds requiring treatment in the highest dose groups in ...

Swiss pharma giant Roche has announced positive Phase I/II data on NXT007 in people with hemophilia A, supporting its ...

Chugai Pharma presents positive data from NXTAGE phase I/II study of NXT007 in people with haemophilia A at ISTH 2025 Congress: Tokyo Tuesday, June 24, 2025, 13:00 Hrs [IST] Chuga ...

Early data suggest Roche’s NXT007 may have the potential to provide haemostatic normalisation in people with haemophilia A. Positive phase I/II data presented at the 2025 International Society ...

NXT007 brings together factor IXa and factor X, proteins required to activate the natural coagulation cascade. 1,2,3 NXT007 is being studied in a robust clinical development programme exploring its ...

NXT007 brings together factor IXa and factor X, proteins required to activate the natural coagulation cascade. 1,2,3 NXT007 is being studied in a robust clinical development programme exploring ...

NXT007 is a next-generation investigational bispecific antibody, being investigated as a prophylactic (preventive) treatment option for people with haemophilia A. 1,2,3 NXT007 was engineered by Chugai ...

NXT007 leverages the Roche Group’s expertise in haemophilia A and bispecific antibody development. Our goal is to bring a next generation prophylactic to our portfolio, offering greater therapeutic ...

NXT007 brings together factor IXa and factor X, proteins required to activate the natural coagulation cascade.1,2,3 NXT007 is being studied in a robust clinical development programme exploring its ...

Positive phase I/II data presented at the 2025 International Society on Thrombosis and Haemostasis (ISTH) Congress show ...